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Abstract
Purpose Janus tyrosine kinases (JAKs) and signal trans-
ducer and activator of transcription factors (STATs),
especially STAT3, are constitutively activated in human
cancers. The function of STAT3 in the pathogenesis of
meningioma remains unknown. In this study, we investi-
gated the role of JAK1/STAT3 regulating vascular endo-
thelial growth factor (VEGF) expression in the occurrence
and progression of human meningioma.
Methods We detected the expression of JAK1, p-JAK1,
STAT3, p-STAT3, and VEGF in human meningioma and
normal dura tissues by RT–PCR, Western blot analysis,
and immunohistochemistry.
Results JAK1, p-JAK1, STAT3, p-STAT3, and VEGF
showed high expression in grade I and grade II meningi-
oma. The level of STAT3 activation was associated with
VEGF expression; all meningioma tumors that expressed
p-STAT3 also expressed VEGF. Both frequency of posi-
tivity and expression were enhanced with increasing tumor
grade; high frequencies and levels were found in grade II
tumors, with no expression detected in normal dura tissues
(P \ 0.05).
Conclusions VEGF is directly regulated by constitutive
STAT3 activity and associated with meningioma differ-
entiation. STAT3 has an important role in the occurrence
and development of human meningioma by regulating
VEGF expression.
Keywords Constitutive activation 
Human meningioma  p-STAT3  STAT3  VEGF
Abbreviations
JAK1 Janus tyrosine kinase 1
p-JAK1 Phosphorylated Janus tyrosine kinase 1
p-STAT3 Phosphorylated signal transducer and activator
of transcription 3
STAT3 Signal transducer and activator of transcription 3
VEGF Vascular endothelial growth factor
Introduction
Constitutive activation of the Janus tyrosine kinase/signal
transducer and activator of transcription (JAK/STAT) sig-
nal pathway is frequently detected in human cancers and
contributes to oncogenesis. JAK1 and STAT3 are activated
in response to interleukin-6 in human fibrosarcoma cells
(Guschin et al. 1995), and the levels are consistently higher
in low-differentiated gliomas than in high-differentiated
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gliomas (Cattaneo et al. 1998). Dephosphorylated JAK1
and STAT3 reduce the expression of STAT3-regulated
VEGF in various human tumor cell lines (Haridas et al.
2009). As well, the JAK1/STAT3 signal pathway plays a
role in cell transformation and carcinogenesis (Coppo et al.
2006; Tian et al. 1994; Tam et al. 2007). STAT3 is a
member of the STAT family of STAT1-4, STAT5a,
STAT5b, and STAT6, which mediates cell survival,
growth, and differentiation in many cancerous cell lines
and human tumors (Bowman et al. 2000; Rubin Grandis
et al. 2000). Constitutively, STAT3 in tumor cells promote
tumor invasion and angiogenesis by regulating the
expression of target genes and modulates fundamental
cellular processes, such as proliferation and differentiation.
Tumor angiogenesis is required for tumor growth and
development stimulated by angiogenic inducers. VEGF,
originally isolated from tumor cells, is one of the major
inducers of tumor angiogenesis and regulates vascular
endothelial proliferation (Ferrara et al. 2003). STAT3alpha
might play a central role in activation of autocrine VEGF
in gliomas (Schaefer et al. 2002). Colon cancer cells
showed inhibited angiogenesis and metastasis with blocked
STAT3 and VEGF expression (Kim et al. 2008). As an
intracellular regulator, STAT3 is involved in tumor vas-
cular remodeling and tumor development by regulating
VEGF expression. Most brain tumors overexpress VEGF,
which leads to an abnormally permeable tumor vasculature.
As a solid tumor, meningioma depends on neovasculari-
zation by angiogenesis for expansion. However, the func-
tion of the JAK1/STAT3 signal pathway through mediating
VEGF expression remains unknown in the pathogenesis of
human meningioma.
In this study, we explored whether VEGF expression
regulated by the constitutive activation of the JAK1/
STAT3 signal pathway might be involved in the occur-
rence and development of human meningioma.
Materials and methods
Reagents
Trizol reagent was from Sigma; the first-strand cDNA
synthesis kit was from Fermentas; the human primers for
JAK1 (accession number NC_000001.10), STAT3 (acces-
sion number NC_000017.10), VEGFa (accession number
NC_000006.11), and Beta-actin (accession number
NC_000007.13) were designed with use of sequence
information in GenBank and synthesized by Invitrogen;
JAK1, p-JAK1 (Tyr1022/1023), p-STAT3 (Tyr705), VEGF,
and Beta-actin primary antibodies were from Santa Cruz
Biotechnology; STAT3 primary antibody was from Cell
Signaling Technology; horseradish peroxidase-conjugated
(HRP) anti-rabbit/mouse IgG secondary antibodies were
from Santa Cruz Biotechnology; the DAB kit was from
Zymed; the lysis buffer was from Promega; and the
enhanced chemiluminescence (ECL) kit was from
Amersham.
Clinical materials
We obtained 40 meningioma specimens (26 from males;
donor mean age 49.0 ± 13.0 years, range 17–72 years)
from the Department of Neurosurgery, the Second Hospital
of Shandong University, China. None of the patients had
undergone any preoperative treatments, such as chemo-
therapy or radiotherapy; histological differentiation was
classified according to the 2000 World Health Organization
classification. As much as 30 cases were grade I menin-
gioma (well differentiated), and 10 were grade II (moder-
ately differentiated). We obtained 6 normal dura samples
from patients with cerebral trauma. The protocol was
approved by the ethics committee of the Second Hospital
of Shandong University, China. The patients gave their
informed consent for use of samples.
One half of each sample was immediately frozen in
liquid nitrogen for RT–PCR and Western blot analysis, and
the other half was fixed in 15% formalin for histological
typing and immunohistochemistry.
RT–PCR
Meningioma and normal samples were homogenized with
1 ml Trizol reagent; total RNA was isolated according to
the manufacturer’s instructions. RNA concentration and
integrity were evaluated by measuring absorbance at 260
and 280 nm, and cDNA was prepared according to the
manufacturer’s instructions for the RT–PCR kit. The
sequence of primers was as follows: JAK1, sense 50-AGTG
CCCTGAGCTACTTGGA-30 and antisense 50-AGGTCAG
CCAGCTCCTTACA-30 (371 bp); STAT3, sense 50-AACT
CTTGGGACCTGGTGTG-30 and antisense 50-CGGACTG
GATCTGGGTCTTA-30 (317 bp); VEGFa, sense 50-CTGC
TGTCTTGGGTGCATTG-30 and antisense 50-TTCACAT
TTGTTGTGCTGTAG-30 (378 bp); Beta-actin, sense
50-GTGGGGCGCCCCAGGCACCA-30 and antisense
50-CTCCTTAATGTCACGCACGATTTC-30 (539 bp). A
20-ll volume reaction for PCR included 1.5 ll cDNA and
1.0 unit Taq polymerase. PCR reaction involved denatur-
ation at 94C for 2 min, then annealing for 32 cycles at
94C, 55C, and 72C for 1 min each, with extension at
72C for 2 min. The PCR products underwent electro-
phoresis on a 1% agarose gel; gene expression was nor-
malized to that of Beta-actin by 1D Image analysis
software (Eastman Kodak).
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Western blot analysis
After being weighed, tumor and normal dura tissues were
homogenized with liquid nitrogen, and lysis buffer was
added to 200 ll; protein concentration was evaluated by
measuring absorbance at 562 nm. Proteins were separated
on 10% SDS–PAGE, then electroblotted on PVDF mem-
brane; the membranes were blocked with 10% non-fat
dry milk in TBS-T overnight at 4C, then incubated
with primary antibodies against JAK1, p-JAK1, STAT3,
p-STAT3, VEGF, and Beta-actin (each dilution 1:1,000)
for 1.5 h at room temperature. After a wash with TBS-T,
membranes were incubated with HRP-conjugated second-
ary antibodies (dilution 1:2,000) for 1 h at room tempera-
ture. Immunoreactivity was detected by use of an ECL kit
for 2–5 min according to the manufacturer’s instructions.
Protein expression was normalized to that of Beta-actin by
1D Image analysis software.
Immunohistochemistry
Normal dura and tumor tissue sections (5 lm thick) were
incubated at 60C for 45 min and immediately deparaffi-
nized in xylene (5 min 9 2), then gradient ethanol (5 min
each in 95%, 90%, 80%, 70%). Endogenous peroxidase
activity was blocked with 3% H2O2 in methanol for
10 min; sections were washed with phosphate buffered
saline (PBS) and treated with antigen retrieval buffer in a
microwave oven to unmask the antigens for 10 min. After a
PBS wash, sections were blocked with diluted normal goat
serum for 20 min, then primary antibodies against JAK1,
p-JAK1, STAT3, p-STAT3, and VEGF (each dilution
1:100) overnight at 4C. After a PBS wash, the appropriate
secondary antibodies were added for 30 min at 37C, then
sections were washed with PBS and underwent DAB col-
oration for 3–5 min. The primary antibodies were substi-
tuted with PBS for negative control tissue slides for each
experiment. The tissue sections were examined by two
independent investigators. Protein expression was classi-
fied as follows (Preusser et al. 2005): (1) cytoplasmic
staining: with 0–15% positive tumor cells was negative;
\50% was low expression, C50% was high expression; (2)
nuclear staining: with no positive tumor cells was negative;
\10% was low expression, C10% was high expression.
Statistical analysis
SPSS v11.0 software (SPSS Inc., Chicago, IL) was used for
statistical analysis. Expression of genes was analyzed by
independent-sample Student t test. The frequency of posi-
tivity of genes in different tissues at the mRNA and protein
levels were tested by Fisher’s exact test. Spearman analysis
was used to assess the correlation between gene expression
and meningioma differentiation. A P \ 0.05 was consid-
ered statistically significant.
Results
mRNA expression of JAK1, STAT3, and VEGFa
upregulated in meningioma
Among 30 grade I meningioma cases, JAK1 expression
was detected in 11; STAT3 expression was detected in all
JAK1-positive cases, and VEGFa expression was detected
in all cases positive for both JAK1 and STAT3 and 1 case
negative for both JAK1 and STAT3. JAK1 and STAT3
were detected at the same time in 8 out of the 10 grade II
cases; VEGFa expression was found in 9 out of 10 grade II
cases, including 8 cases positive for both JAK1 and
STAT3. The frequencies of positivity and level of genes
were high in grade I and II cases; no expression was found
in normal dura tissues; high levels were found in grade II
tissues (Table 1, Figs. 1, 2; P \ 0.05).
Correlation between meningioma differentiation
and frequency of positivity and expression
of genes by RT–PCR
The frequency of positivity and expression of genes were
correlated with meningioma differentiation status (Table 1,
Figs. 1, 2). The relative expression of JAK1 was strongly
correlated with that of STAT3, the expression of STAT3
was also strongly correlated with that of VEGFa (Table 2).




(n = 30) P#
Grade II tumor
(n = 10) P#
r P*
Positive Positive Positive
JAK1 0 11 (36.7%) 8 (80.0%) 0.376 0.017
STAT3 0 11 (36.7%) 8 (80.0%) 0.376 0.017
VEGFa 0 12 (40.0%) 9 (90.0%) 0.434 0.005
# P \ 0.05, compared with normal dura tissue or grade I tumor. The inter-class correlation coefficients assess the correlations between frequency
of positivity and tumor differentiation status. * P \ 0.05 was considered statistically significant
J Cancer Res Clin Oncol (2010) 136:981–988 983
123
Constitutive activation of STAT3 upregulated VEGF
protein expression in meningioma
Among grade I meningioma cases, JAK1 and STAT3
expression were found in the same 11 out of 30 cases;
VEGF was highly expressed in all cases expressing both
JAK1 and STAT3; p-JAK1 and p-STAT3 were detected in
8 cases expressing both JAK1 and STAT3. The ratio of
p-JAK1 to p-STAT3 was 72.7% (8/11). Among grade II
meningioma cases, JAK1, STAT3, and VEGF were
detected in the same 8 out of 10 cases; p-JAK1 and
p-STAT3 expression were detected in the same 7 cases
expressing JAK1, STAT3, and VEGF. The ratio of p-JAK1
to p-STAT3 was 87.5% (7/8). The relative frequency of
positivity and expression of p-JAK1 and p-STAT3 were
positively correlated with histological status of meningi-
oma; high levels were found in grade II tumors (Tables 3,
4, Figs. 2, 3).
Correlation analysis of JAK1 versus STAT3, STAT3
versus VEGF, p-JAK1 versus p-STAT3, p-JAK1 versus
Fig. 1 RT–PCR analysis of
mRNA expression of JAK1,
STAT3, and VEGFa in normal
dura and meningioma tissues.
a mRNA levels of JAK1,
STAT3, VEGFa. Beta-actin
is a loading control.
b Quantification of mRNA
levels of JAK1, STAT3, and
VEGFa normalized to that of
Beta-actin. *P \ 0.05 compared
with normal dura tissue or grade
I tumor
Fig. 2 Plots of gene expression
from RT-PCR and Western blot
analysis in normal dura and
meningioma tissues normalized
to that of Beta-actin. Relative
mRNA expression of JAK1,
STAT3, and VEGFa in a normal
dura tissue, b grade I tissue, and
c grade II tissue. Relative
protein expression of JAK1,
p-JAK1, STAT3, p-STAT3, and
VEGF in d normal dura tissue,
e grade I tissue, and f grade II
tissue
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VEGF, and p-STAT3 versus VEGF in grade I and grade II
tumors showed strong correlation (Table 4). All meningi-
oma tumors positive for p-STAT3 also showed VEGF
expression. VEGF expression was also correlated with
meningioma differentiation (Table 3; P \ 0.05).
Constitutive activation of STAT3 upregulates VEGF
protein expression associated with human meningioma
differentiation
Results of frequency of positivity seen on immunohisto-
chemistry were in agreement with those seen on Western
blot analysis (Table 3). Among grade I tumors, 9 cases
expressed low levels of JAK1 and STAT3 and 2 high levels;
low expression was found in all p-JAK1- and p-STAT3-
positive cases (8/8); 9 cases expressed a low level of VEGF
and 2 a high level. Among grade II cases, both JAK1 and
STAT3 were highly detected in 7, with low expression in 1
case; high levels of p-JAK1 and p-STAT3 were found in 6
cases, and low levels in 1 case; a high level of VEGF was
found in all VEGF-positive cases (8/8). Relative frequency
of positivity and levels of p-JAK1 and p-STAT3 were
higher in grade II than in grade I tumors. Tumor tissues
expressing p-STAT3 also expressed VEGF; the high levels
were found in grade II tumors. Co-expression of p-STAT3
and VEGF was significantly correlated with meningioma
differentiation (Tables 3, 5, Fig. 4; P \ 0.05).
Discussion
The JAK/STAT signal pathway has been reported to be
involved in the oncogenesis of human cancers. STATs are
selectively activated mainly by activated JAKs (including
JAK1, JAK2, JAK3, and TYK2), which leads to STAT
protein activation, nuclear translocation, and regulation of
target gene expression. The function of the JAK1/STAT3
signal pathway is best explained in SCID mice models:
JAK1-/- and STAT3-/- mice die during embryogenesis
because of impaired neurological and lymphoid develop-
ment (Rodig et al. 1998; Takeda et al. 1997; Akira 1999).
The JAK1/STAT3 signal pathway plays a critical role in cell
transformation and carcinogenesis (Coppo et al. 2006; Tian
et al. 1994; Tam et al. 2007). p-STAT3 is dysregulated in
various human tumors, including head and neck squamous
cell cancer (Rubin Grandis et al. 2000), leukemia (Carlesso
et al. 1996), multiple myeloma (Bharti et al. 2003), and
lymphomas (Weber-Nordt et al. 1996). Abnormal STAT3
activity induces permanent changes in gene expression that
ultimately lead to a malignant tumor phenotype. Constitutive
activation of STAT3 is associated with growth stimulation
and anti-apoptotic effects in malignant disease.
In our study, we found JAK1 was significantly corre-
lated with STAT3, and they were both over-expressed in
meningioma, with the highest levels in grade II tumors; no
expression was found in normal dura tissues. The expres-
sion of JAK1 and STAT3 was associated with tumor
differentiation status (Table 5, Fig. 4; P \ 0.05). Other
studies have shown JAK1 and STAT3 markedly down-
regulated in the normal adult rat brain (De-Fraja et al.
2000; Gautron et al. 2006). However, JAK and STAT
families of proteins are highly expressed and are important
effectors in brain tumors (Magrassi et al. 1999). Our data
showed varied expression of total JAK1 and STAT3 by
tumor differentiation status, which suggests that the
expression pattern of the JAK1/STAT3 signal pathway is
associated with the development of meningioma.
Table 2 Correlation analysis of JAK1 or STAT3 and VEGF
expression normalized to that of Beta-actin by RT–PCR
Grade I tumor (n = 30) Grade II tumor (n = 10)
r P r P
JAK1/STAT3 0.944 0.000 0.741 0.014
STAT3/VEGFa 0.855 0.000 0.780 0.008
Table 3 Frequency of positivity of JAK1, p-JAK1, STAT3,







(n = 30) P#
Grade II
tissue
(n = 10) P#
r P*
Positive Positive Positive
JAK1 0 11 (36.7%) 8 (80%) 0.376 0.017
p-JAK1 0 8 (26.7%) 7 (70%) 0.388 0.013
STAT3 0 11 (36.7%) 8 (80%) 0.376 0.017
p-STAT3 0 8 (26.7%) 7 (70%) 0.388 0.013
VEGF 0 11 (36.7%) 8 (80%) 0.376 0.017
# P \ 0.05 compared with normal dura tissue or grade I meningioma
tissue. The inter-class correlation coefficients assess the correlations
between frequency of positivity and tumor differentiation status.
* P \ 0.05 was considered statistically significant
Table 4 Correlation analysis of JAK1 or STAT3 activation and
VEGF expression normalized to that of Beta-actin by Western blot
analysis
Grade I tumor (n = 30) Grade II tumor (n = 10)
r P r P
JAK1/STAT3 0.821 0.000 0.655 0.040
p-JAK1/p-STAT3 0.951 0.000 0.653 0.041
STAT3/VEGF 0.832 0.000 0.654 0.040
p-JAK1/VEGF 0.767 0.000 0.876 0.001
p-STAT3/VEGF 0.794 0.000 0.914 0.000
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Tyrosine phosphorylation is crucial for the function of
STAT proteins regulated by the receptor-driven JAK cata-
lytic activity (Lee et al. 1997; Turkson and Jove 2000).
Tyrosine phosphorylation of STAT3 (p-STAT3) is a critical
step for translocation to the nucleus and regulation of the
expression of target genes. We found that the expression of
p-JAK1 correlated with that of p-STAT3 in meningioma on
Western blot analysis and immunohistochemistry; the rel-
ative expression differed by meningioma grade, with the
high level in grade II tumors. The relative frequency of
positivity and level of p-JAK1 and p-STAT3 were positively
correlated with histological differentiation of meningioma
(Tables 3, 5, Fig. 4; P \ 0.05), which confirms that the
activated JAK1/STAT3 signal pathway is associated with
progression of human meningioma. A high level of
p-STAT3 reduces patient survival in hormone-refractory
prostate cancer, which suggests that activation of the JAK1/
STAT3 signal pathway is involved in development of this
Fig. 3 Western blot analysis of protein expression of JAK1, p-JAK1,
STAT3, p-STAT3, and VEGF. a Protein level of JAK1, p-JAK1,
STAT3, p-STAT3, and VEGF in normal dura and tumor tissue. Beta-
actin was a loading control. b Relative protein expression of JAK1,
p-JAK1, STAT3, p-STAT3, and VEGF normalized to that of Beta-
actin. *P \ 0.05 compared with normal dura tissues or grade I tumor
Table 5 Association of gene
expression with tumor







Grade I tumor Grade II tumor r P
Low expression High expression Low expression High expression
JAK1 9 2 1 7 0.685 0.001
p-JAK1 8 0 1 6 0.873 0.000
STAT3 9 2 1 7 0.685 0.001
p-STAT3 8 0 1 6 0.873 0.000
VEGF 9 2 0 8 0.809 0.000
Fig. 4 Immunohistochemistry of meningioma tissues (normal dura
tissues not shown): a, c, e, g, i Negative control of JAK1, p-JAK1,
STAT3, p-STAT3, and VEGF, respectively, in meningioma tissue.
Positive protein expression of b JAK1 mainly in cytoplasm, d p-JAK1
mainly in cytoplasm, f STAT3 mainly in cytoplasm, h p-STAT3
mainly in nucleus, and j VEGF mainly in cytoplasm. Original
magnification 6009
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cancer (Tam et al. 2007). So constitutive activation of
JAK1/STAT3 signal pathway can be considered as an
oncogenic event in the occurrence and development of
tumors (Knoops et al. 2008; Zhang et al. 2000).
Protein phosphorylation has an important role in cellular
processes because it regulates the functional activities of
signal proteins. Activated by JAKs, phosphorylated STATs
translocate from the cytoplasm to nucleus, where they
regulate transcription and protein expression of target
genes. Downstream targets of STAT3, such as bcl-xl, cyclin
D1, and VEGF, are important in preventing apoptosis,
enhancing invasion, and promoting metastasis and angio-
genesis (Haridas et al. 2009; Catlett-Falcone et al. 1999;
Schaefer et al. 2002; Mahboubi et al. 2001). Constitutive
activation of STAT3 induces changes that lead to initiation
and/or maintenance of oncogenesis. As a significant pre-
dictive factor of prognosis in patients with solid tumors,
angiogenesis is essential for tumor growth, progression, and
metastasis (Folkman 2001; Ohta et al. 1996). VEGF is
considered as a major regulator of angiogenesis in various
brain tumors (Berkman et al. 1993; Huang et al. 2005). As a
solid tumor, meningioma depends on neovascularization
through angiogenesis for expansion. We found high mRNA
and protein levels of VEGF associated with meningioma
grade. Tumor tissues expressing p-STAT3 also expressed
VEGF, and p-STAT3 was significantly correlated with
VEGF expression (Tables 3, 4, 5 and Figs. 2, 3, 4;
P \ 0.05). STAT3 can directly bind the VEGF promoter to
upregulate VEGF expression in many tumors (Niu et al.
2002; Wei et al. 2003). p-STAT3 induces overexpression of
VEGF, which is decreased during angiogenesis by inhibi-
tion with antagonists of VEGF–VEGFR signaling (Chen
et al. 2008). So p-STAT3 is involved in angiogenesis by
mediating VEGF expression, which agrees with other
researches (Schaefer et al. 2002; Loeffler et al. 2005; Wang
et al. 2004). The production and action of VEGF regulation
by activated STAT3 is necessary in the occurrence and
development of human meningioma.
Conclusion
VEGF expression is significantly correlated with STAT3
activity, and co-expression of p-STAT3 and VEGF is
associated with meningioma differentiation status. STAT3
is the point of convergence for the meningioma angiogenic
event as the JAK1/STAT3 signal pathway mediates VEGF
expression. So STAT3 has an important role in the
occurrence and development of human meningioma.
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